Showing 1 to 10 of 10 results
FDA Weighs Removing Menopause Hormone Therapy Warnings Amidst New Research
The FDA is considering removing health warnings from some menopause hormone therapy treatments following new research that suggests previous safety concerns were overstated, prompting debate among experts.
FDA Weighs Removing Menopause Hormone Therapy Warnings Amidst New Research
The FDA is considering removing health warnings from some menopause hormone therapy treatments following new research that suggests previous safety concerns were overstated, prompting debate among experts.
Progress
20% Bias Score
Underdiagnosed GSM Impacts Millions of Postmenopausal Women
Affecting 27-84% of postmenopausal women, Genitourinary Syndrome of Menopause (GSM) causes vaginal dryness, pain during intercourse, and urinary issues, often misdiagnosed as urinary tract infections; effective treatments are available, including hormone therapy and vaginal moisturizers.
Underdiagnosed GSM Impacts Millions of Postmenopausal Women
Affecting 27-84% of postmenopausal women, Genitourinary Syndrome of Menopause (GSM) causes vaginal dryness, pain during intercourse, and urinary issues, often misdiagnosed as urinary tract infections; effective treatments are available, including hormone therapy and vaginal moisturizers.
Progress
24% Bias Score
FDA Panel Urges Removal of Black Box Warnings for Low-Dose Vaginal Estrogen
An FDA panel recently recommended removing black box warnings from low-dose vaginal estrogen treatments due to concerns that they overstate risks and deter women from using beneficial menopause medications; this decision follows decades of evolving understanding of HRT safety and efficacy.
FDA Panel Urges Removal of Black Box Warnings for Low-Dose Vaginal Estrogen
An FDA panel recently recommended removing black box warnings from low-dose vaginal estrogen treatments due to concerns that they overstate risks and deter women from using beneficial menopause medications; this decision follows decades of evolving understanding of HRT safety and efficacy.
Progress
48% Bias Score
Delayed POI Diagnosis Underscores Need for Improved Medical Care and Education
Corinna Bordolli, 29, was diagnosed with premature ovarian insufficiency (POI) at 15, experiencing various symptoms until receiving appropriate hormone replacement therapy (HRT) after self-diagnosing. Her case highlights delayed diagnosis challenges and the need for better medical education and trea...
Delayed POI Diagnosis Underscores Need for Improved Medical Care and Education
Corinna Bordolli, 29, was diagnosed with premature ovarian insufficiency (POI) at 15, experiencing various symptoms until receiving appropriate hormone replacement therapy (HRT) after self-diagnosing. Her case highlights delayed diagnosis challenges and the need for better medical education and trea...
Progress
32% Bias Score
AEMPS Seizes Unregulated Hormone Pellets in Spain
The Spanish Agency of Medicines and Medical Devices (AEMPS) has seized hormone pellets from two Valencian pharmacies due to inadequate production methods, lack of sterility, and unsubstantiated claims of anti-aging benefits, prompting a nationwide review of their distribution and use.
AEMPS Seizes Unregulated Hormone Pellets in Spain
The Spanish Agency of Medicines and Medical Devices (AEMPS) has seized hormone pellets from two Valencian pharmacies due to inadequate production methods, lack of sterility, and unsubstantiated claims of anti-aging benefits, prompting a nationwide review of their distribution and use.
Progress
60% Bias Score
Menopause Misconceptions: Beyond Hot Flashes
This article dispels common misconceptions about menopause, highlighting the wide range of symptoms, the role of hormone therapy, and the importance of addressing the issue openly.
Menopause Misconceptions: Beyond Hot Flashes
This article dispels common misconceptions about menopause, highlighting the wide range of symptoms, the role of hormone therapy, and the importance of addressing the issue openly.
Progress
12% Bias Score
FDA Panel Recommends Removing Black Box Warning from Some Menopause Treatments
The FDA may remove the black box warning on estrogen-containing menopause treatments following an expert panel's recommendation, based on updated analyses suggesting that hormone therapy may not increase risks as previously thought, particularly when initiated before age 60 or within 10 years of men...
FDA Panel Recommends Removing Black Box Warning from Some Menopause Treatments
The FDA may remove the black box warning on estrogen-containing menopause treatments following an expert panel's recommendation, based on updated analyses suggesting that hormone therapy may not increase risks as previously thought, particularly when initiated before age 60 or within 10 years of men...
Progress
36% Bias Score
France to Revise Hormone Replacement Therapy Guidelines in 2026
Hormone Replacement Therapy (HRT), used to treat menopausal symptoms, faced controversy after a 2002 US study linked it to increased health risks; however, this study's methodology is now debated, and France is revising its HRT guidelines in 2026 to reflect updated research and address past misconce...
France to Revise Hormone Replacement Therapy Guidelines in 2026
Hormone Replacement Therapy (HRT), used to treat menopausal symptoms, faced controversy after a 2002 US study linked it to increased health risks; however, this study's methodology is now debated, and France is revising its HRT guidelines in 2026 to reflect updated research and address past misconce...
Progress
36% Bias Score
Primary Ovarian Insufficiency: Global Prevalence, Symptoms, and Impacts on Women's Health
Primary Ovarian Insufficiency (POI), affecting 3.7% of women globally, causes premature ovarian failure before age 40, leading to symptoms like irregular periods, hot flashes, and mood swings; delayed diagnosis often results in significant impacts on quality of life.
Primary Ovarian Insufficiency: Global Prevalence, Symptoms, and Impacts on Women's Health
Primary Ovarian Insufficiency (POI), affecting 3.7% of women globally, causes premature ovarian failure before age 40, leading to symptoms like irregular periods, hot flashes, and mood swings; delayed diagnosis often results in significant impacts on quality of life.
Progress
24% Bias Score
Australia Invests $573 Million in Women's Health, Lowering Costs for HRT and Contraceptives
The Australian government will invest $573 million in women's health, lowering costs for hormone replacement therapies and contraceptives starting March 1st, including Medicare rebates for menopause assessments and increased funding for long-acting contraceptives to improve access for at least half ...
Australia Invests $573 Million in Women's Health, Lowering Costs for HRT and Contraceptives
The Australian government will invest $573 million in women's health, lowering costs for hormone replacement therapies and contraceptives starting March 1st, including Medicare rebates for menopause assessments and increased funding for long-acting contraceptives to improve access for at least half ...
Progress
56% Bias Score
Showing 1 to 10 of 10 results